Oral Semaglutide vs. Sitagliptin: PIONEER 3 Study
- Ms. Silpa Rani Gajavalli
- Sep 9
- 2 min read
Updated: Sep 10
Rosenstock J et al. conducted the PIONEER 3 trial to compare the effectiveness of oral Semaglutide against Sitagliptin in adult Type 2 diabetes patients who were not adequately controlled on Metformin alone or with sulfonylurea. This study robustly evaluated the impacts on HbA1c reduction and the changes in body weight from baseline (1).
Study Summary
About the Author
Ms. Silpa Rani Gajavalli is a postgraduate in pharmaceutical science (M Pharmacy). She has a wealth of academic experience and is passionate about Medical Writing. Silpa regularly posts articles on the latest advancements in medical research, pharmacological agents, clinical aspects of medicine, innovative treatments, regulatory aspects, and landmark clinical trials.
Abbreviations
T2DM: Type 2 diabetes mellitus; HbA1c: Haemoglobin A1c; MET: Metformin;
Reference
Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, et al; PIONEER 3 Investigators. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019. Apr 16;321(15):1466-1480.
Disclaimer
The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to content@rxnews.in
Comments